Drug intelligence / Profile preview

IPX239

Development stage: Discontinued
Lead developer: Amneal Pharmaceuticals
Administration: Transdermal

Overview

IPX239 was a drug candidate licensed by Impax Laboratories from Durect for the treatment of postherpetic neuralgia. Publicly available information regarding its specific mechanism of action, molecular modality, or further development status beyond the initial licensing agreement is not available, suggesting that its development may not have progressed significantly or was discontinued.

Beyond the preview

Go deeper on IPX239.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPX239.

Explore the full profile